Navigation Links
RVX-208 Data Demonstrates Increase in Functional HDL Particles
Date:11/10/2008


Prebeta-HDL generation and improved HDL functionality are distinguishing

factors

TSX Exchange Symbol: RVX

NEW ORLEANS, LA, Nov. 10 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today key scientific data was presented in an oral presentation highlighting the novel features of RVX-208 at the American Heart Association Scientific Meeting. The presentation titled "Compound RVX-208 Modulates HDL-C Levels and Function in Non-human Primates and in Early Human Trials" was presented by Dr. Jacques Genest.

Dr. Jacques Genest, MD, Director of the Division of Cardiology at McGill University Health Centre/Royal Victoria Hospital said, "We continue to be excited about the data that is being generated for RVX-208. It is important that our colleagues have access to this promising data which is why we have presented at this prominent conference. Resverlogix's novel drug demonstrated the ability to increase the production of ApoA-I and functional HDL. Notably we saw increases in prebeta-HDL particles, which improve HDL's ability to mediate cholesterol efflux."

"Today we presented interesting and consistent data from African Green monkey studies and our Phase 1a human clinical trial at the AHA," stated Dr. Jan Johansson, MD, Ph.D., Senior Vice President, Medical Affairs of Resverlogix. "The pharmacodynamic data from human healthy volunteers of which the majority had low HDL demonstrated that we have seen significant increases in ApoA-I production and HDL functionality, consistent with previous findings in the African Green monkey studies. Further investigation of the effect of RVX-208 on the HDL metabolic pathway is ongoing in humans and animals to establish the mechanisms of action and therapeutic potential in treating atherosclerotic cardiovascular disease."

During the presentation Dr. Genest reported that in an African Green monkey study treatment with RVX-208 resulted in a highly
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. RVX-208 Exploratory Study Illustrates Early Potential for Alzheimers Disease
2. International Steering Committee for RVX-208 IVUS Trial Formed
3. Phase 1b/2a Program Commences for RVX-208
4. Industry Leaders Select Resverlogixs RVX-208
5. Dosing for RVX-208 Phase 1a Clinical Study Completed
6. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
7. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
8. Study From the University of Texas M.D. Anderson Cancer Center Demonstrates That AHCC(R) is Safe in Combination With Most Chemotherapeutic Agents
9. Vaxart Demonstrates Efficacy of Oral Avian Flu Vaccine in Preclinical Studies
10. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
11. SuperGens MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... August 31, 2015 , ... Proove Biosciences, Inc. is a finalist for the ... Tech Awards. , Now in its 22nd year, this premier awards event celebrates the ... the nation and around the world. The OC Tech Alliance will announce all winners ...
(Date:8/28/2015)... According to a new market ... Systems, Thawing Equipment, Alarms), by Biospecimen (Human Tissue, Stem ... User - Global Forecast to 2020", published by MarketsandMarkets, ... 3,731.03 Million by 2020 from USD 2,150.48 Million in ... and 2020. Browse 74 Tables and ...
(Date:8/28/2015)... , Aug. 28, 2015 /PRNewswire/ - RepliCel Life ... regenerative medicine company focused on the development of ... the quarter ended June 30, 2015, corporate highlights, ... management report are available at www.sedar.com ,  ... "RepliCel expects to launch its ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... ... opportunity for venture capital funds, investment firms and animal health companies to hear ... have raised $160 million. Several have also received licensing agreements or distribution contracts. ...
Breaking Biology Technology:Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 2Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 3Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 4Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3
... by Strong Revenue Growth, Conference Call and Webcast to Be Held Today at 5:00 p.m. ET (22:00 CET), ... Q1 2008 (millions) Q1 2007 Comparison ... 164.5% increase Naglazyme Net Product Revenue ... Aldurazyme (net sales by Genzyme) $36.8 ...
... ... - Product revenues increased 30% to a record $59.7 million ... 28,600 new pulse oximeters ... April 29, 2008 Masimo,Corporation (Nasdaq: MASI ), the inventor of Pulse CO-Oximetry and,Measure-Through-Motion-and-Low-Perfusion ...
... transmit medical images via cellular phones that has ... researcher has the potential to provide sophisticated radiological diagnoses ... lacking access to such technology. This would include millions ... areas of developed countries who live considerable distances from ...
Cached Biology Technology:BioMarin Announces First Quarter 2008 Financial Results 2BioMarin Announces First Quarter 2008 Financial Results 3BioMarin Announces First Quarter 2008 Financial Results 4BioMarin Announces First Quarter 2008 Financial Results 5BioMarin Announces First Quarter 2008 Financial Results 6BioMarin Announces First Quarter 2008 Financial Results 7BioMarin Announces First Quarter 2008 Financial Results 8BioMarin Announces First Quarter 2008 Financial Results 9BioMarin Announces First Quarter 2008 Financial Results 10BioMarin Announces First Quarter 2008 Financial Results 11Masimo Reports First Quarter 2008 Financial Results 2Masimo Reports First Quarter 2008 Financial Results 3Masimo Reports First Quarter 2008 Financial Results 4Masimo Reports First Quarter 2008 Financial Results 5Masimo Reports First Quarter 2008 Financial Results 6Masimo Reports First Quarter 2008 Financial Results 7Masimo Reports First Quarter 2008 Financial Results 8Masimo Reports First Quarter 2008 Financial Results 9Masimo Reports First Quarter 2008 Financial Results 10Researchers develop method for transmitting medical images via cell phones 2Researchers develop method for transmitting medical images via cell phones 3Researchers develop method for transmitting medical images via cell phones 4
(Date:8/10/2015)... BOSTON and TELTOW, Germany ... SensoMotoric Instruments (SMI), a world leader in Eye ... the completion of its OEM Eye Tracking Platform for ... Eye Tracking Platform contains reference designs for seamless integration ... kiosk systems, virtual reality HMDs and augmented reality smart ...
(Date:8/6/2015)... REDWOOD CITY, Calif. , Aug. 6, 2015 ... (D-Silicon Valley) will visit Crossmatch ™ to ... secure networks and protect data. Crossmatch is a ... solutions whose technologies and expertise are helping federal ... operational efficiency and security.   "The ...
(Date:8/6/2015)... , Aug. 6, 2015 Synaptics ... of human interface solutions, today announced collaboration with ... on Windows 10. Microsoft leveraged Synaptics, deep expertise ... operating system. Through stringent testing, ... fully certified with Microsoft,s Precision TouchPad (PTP) specification ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... from the University of Santiago de Compostela (USC) have ... The results show that the principal goal of young ... The most antisocial among them place greater importance on ... most importance on are to do with leaving home, ...
... Research currently being undertaken at the University of ... Abdominal Aortic Aneurysms (AAA) in men. In her ... into the causes of the male predominance of AAA, ... disease. Preliminary results from the study will be showcased ...
... KNOXVILLE -- By examining 800,000-year-old polar ice, scientists increasingly are ... melt and that carbon dioxide has become more abundant in ... Jrme Chappellaz has been examining ice cores collected from deep ... studies on the interconnecting air spaces of old snow -- ...
Cached Biology News:Teenagers want to finish their studies and leave home 2Increased likelihood of male death from disease 2Scientist links increase in greenhouse gases to changes in ocean currents 2
sterile filtered, off the clot, all male donors, Total Protein: 4.5 to 8.5 g/dl...
Recombinant Mouse MMP-9, CF...
Human/Mouse/Rat JNK Pan Specific Affinity Purified PAb...
Blue Standard is 3-cyano-7-hydroxycoumarin....
Biology Products: